AJP - Regulatory, Integrative and Comparative Physiology, Vol 265, Issue 3 625-R631, Copyright © 1993 by American Physiological Society

ARTICLES

Cardiovascular consequences of microinjection of vasopressin and angiotensin II in the area postrema

V. L. Lowes, L. E. McLean, N. W. Kasting and A. V. Ferguson
Department of Physiology, Queen's University, Kingston, Ontario, Canada.

Microinjection of angiotensin II (ANG II) into the area postrema (AP) of urethan-anesthetized male Sprague-Dawley rats elicited statistically significant increases in mean arterial blood pressure at doses ranging from 10 pg to 500 ng (10 pg, mean +/- SE, 10.8 +/- 1.1 mmHg, P < 0.001; 250 ng, 15.2 +/- 2.6 mmHg, P < 0.001). Heart rate was also significantly increased at doses > 10 pg, although these increases were not dose dependent. Systemic administration of losartan (Dup-753), an AT1 antagonist, was able to significantly reduce the pressor response to 250 ng ANG (post-losartan: 81.9 +/- 9.5% reduction in blood pressure response, P < 0.0001), whereas PD123319, an AT2 antagonist, was without significant effect (P > 0.1). Microinjection of vasopressin (VP) (10 pg-500 ng) into the AP also resulted in statistically significant increases in blood pressure at doses ranging from 10 to 100 pg (10 pg, 7.0 +/- 1.5 mmHg, P < 0.05) and 100-500 ng (250 ng, 12.2 +/- 1.8 mmHg, P < 0.0001). Small but significant changes in heart rate were observed only at 100 pg and 100 ng. Systemic administration of a V1 antagonist significantly attenuated the increases in blood pressure in response to 50, 100, and 250 ng VP (250 ng, post-V1 antagonist: 66.4 +/- 8.6% reduction in blood pressure response, P < 0.001), whereas [desamino,D-Arg8]vasopressin (DDAVP), a V2 agonist, had a depressor effect when microinjected directly into the AP (250 ng, -9.9 +/- 1.6 mmHg, P < 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. B. Nahey and J. P. Collister ANG II-induced hypertension and the role of the area postrema during normal and increased dietary salt Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H694 - H700. [Abstract] [Full Text] [PDF]

				R. Ma, H. D. Schultz, and W. Wang Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H15 - H22. [Abstract] [Full Text] [PDF]

				J.-L. Liu, H. Murakami, M. Sanderford, V. S. Bishop, and I. H. Zucker ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H342 - H350. [Abstract] [Full Text] [PDF]

				L. Xu, J. P. Collister, J. W. Osborn, and V. L. Brooks Endogenous ANG II supports lumbar sympathetic activity in conscious sodium-deprived rats: role of area postrema Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1998; 275(1): R46 - R55. [Abstract] [Full Text] [PDF]

				J. P. Collister and J. W. Osborn Area postrema lesion attenuates the long-term hypotensive effects of losartan in salt-replete rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1998; 274(2): R357 - R366. [Abstract] [Full Text] [PDF]

				J. P. Collister, B. J. Hornfeldt, and J. W. Osborn Hypotensive Response to Losartan in Normal Rats : Role of Ang II and the Area Postrema Hypertension, March 1, 1996; 27(3): 598 - 606. [Abstract] [Full Text]